Comlek Savas
Department of Anesthesiology and Reanimation, Gayrettepe 90790Florence Nightingale Hospital, Istanbul, Turkey.
J Oncol Pharm Pract. 2020 Oct;26(7):1750-1753. doi: 10.1177/1078155220904994. Epub 2020 Feb 19.
Development of hypersensitivity pneumonitis has been reported in association with combination chemotherapy consisting of gemcitabine and paclitaxel. However, diagnosis of this condition is based on computed tomography imaging and correlative bronchoalveolar findings on bronchoscopy. Although transient elevation of the tumor marker CA 15-3 has been reported in patients with interstitial pneumonitis associated with collagen disease, elevation of this marker during drug-induced hypersensitivity pneumonitis has not been reported yet.
In this report, we describe a 74-year-old metastatic schwannoma patient with drug-induced pneumonitis secondary to combined gemcitabine and paclitaxel treatment associated with transient elevation of CA 15-3.Management and outcome: The patient responded to steroid treatment with clinical and radiological improvement, and CA 15-3 levels returned to normal within four weeks.
These findings suggest that blood CA 15-3 level has the potential to be used as a marker to monitor drug-induced pneumonitis.
已有报道称，吉西他滨和紫杉醇联合化疗会引发过敏性肺炎。然而，该病症的诊断基于计算机断层扫描成像以及支气管镜检查中相关的支气管肺泡检查结果。尽管有报道称，患有与胶原病相关的间质性肺炎的患者肿瘤标志物CA 15-3会出现短暂升高，但药物性过敏性肺炎期间该标志物升高的情况尚未见报道。
在本报告中，我们描述了一名74岁的转移性神经鞘瘤患者，其在接受吉西他滨和紫杉醇联合治疗后出现药物性肺炎，并伴有CA 15-3短暂升高。
患者对类固醇治疗有反应，临床和影像学表现均有改善，且CA 15-3水平在四周内恢复正常。
这些发现表明，血液CA 15-3水平有可能用作监测药物性肺炎的标志物。
